Notice: This company has been marked as potentially delisted and may not be actively trading. NYSE:MNK Mallinckrodt (MNK) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Mallinckrodt Stock (NYSE:MNK) 30 days 90 days 365 days Advanced Chart Ad WealthPressYour chance to get on the next “60-Second Trade”Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!Just head over here! Get Mallinckrodt alerts:Sign Up Key Stats Today's Range$0.07▼$0.1350-Day Range$0.14▼$0.7552-Week Range$0.75▼$6.42Volume39,227 shsAverage Volume2.62 million shsMarket Capitalization$1.58 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.Read More… Receive MNK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mallinckrodt and its competitors with MarketBeat's FREE daily newsletter. Email Address MNK Stock News HeadlinesMallinckrodt Completes Divestiture of Therakos® BusinessDecember 2, 2024 | finance.yahoo.comMallinckrodt to Present at Jefferies London Healthcare ConferenceNovember 15, 2024 | uk.finance.yahoo.comWhy I'm telling friends to avoid gold stocksBack in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."December 22, 2024 | DTI (Ad)Mallinckrodt to Report Earnings Results for Third Quarter 2024October 24, 2024 | finance.yahoo.comHudson Bay Capital Management LP Acquires New Stake in Mallinckrodt PLCOctober 22, 2024 | finance.yahoo.comMallinckrodt Announces an Expanded Rollout of the INOmax® EVOLVE™ DS Delivery System in U.S. HospitalsOctober 10, 2024 | finance.yahoo.comMallinckrodt plc: THERAKOS CELLEX Photopheresis System Receives CE Certificate Under the European Union Medical Device Regulation (EU MDR)September 3, 2024 | finanznachrichten.deMallinckrodt plc Reports Second Quarter 2024 Financial Results and Raises Full Year GuidanceAugust 6, 2024 | stockhouse.comSee More Headlines MNK Stock Analysis - Frequently Asked Questions How were Mallinckrodt's earnings last quarter? Mallinckrodt plc (NYSE:MNK) released its quarterly earnings results on Tuesday, August, 4th. The company reported $1.89 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.55. The firm's revenue for the quarter was down 14.9% compared to the same quarter last year. Read the conference call transcript. What other stocks do shareholders of Mallinckrodt own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mallinckrodt investors own include Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Micron Technology (MU), Endo International (ENDP), Bausch Health Companies (BHC), Meta Platforms (META) and Gerdau (GGB). Company Calendar Last Earnings8/04/2020Today12/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:MNK CUSIPN/A CIK1567892 Webwww.mallinckrodt.com Phone(531) 696-0000FaxN/AEmployees2,700Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($116.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net Margins-82.59% Pretax MarginN/A Return on Equity20.32% Return on Assets2.49% Debt Debt-to-Equity Ratio1.18 Current Ratio0.57 Quick Ratio0.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$47.48 per share Price / Book0.00Miscellaneous Outstanding Shares13,170,000Free Float13,131,000Market Cap$1.58 million OptionableNot Optionable BetaN/A 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report This page (NYSE:MNK) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mallinckrodt plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Mallinckrodt With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.